Glucotrack reports positive final first-in-human CBGM study results with MARD 7.7%

Glucotrack, Inc.

Study met all endpoints; MARD 7.7% across 122 matched pairs, 99% data capture, no serious adverse events.
92% of readings in green zone of Diabetes Technology Society Error Grid, none in unsafe zones.
Ten participants with Type 1 or Type 2 diabetes; device implanted via subclavian vein, monitored 4 days.
Glucotrack expects to initiate long-term early feasibility study in Q3 2025.
OneTwo Analytics applied AI/ML analytics to validate performance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.